Search Results - "Rizack, T"

A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study by Monk, B.J., Brady, M.F., Aghajanian, C., Lankes, H.A., Rizack, T., Leach, J., Fowler, J.M., Higgins, R., Hanjani, P., Morgan, M., Edwards, R., Bradley, W., Kolevska, T., Foukas, P., Swisher, E.M., Anderson, K.S., Gottardo, R., Bryan, J.K., Newkirk, M., Manjarrez, K.L., Mannel, R.S., Hershberg, R.M., Coukos, G.

“…A phase 2, randomized, placebo-controlled trial was conducted in women with recurrent epithelial ovarian carcinoma to evaluate the efficacy and safety of…”
Get full text

A phase II, randomized, double-blind, placebo-controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: A Gynecologic Oncology Group partners study by Monk, B.J, Brady, M.F, Aghajanian, C, Lankes, H, Rizack, T, Leach, J.W, Fowler, J.M, Higgins, R.V, Hanjani, P, Morgan, M.A

Get full text

Failure to cure colorectal liver metastases patients quantified the impact of the liver surgical specialist by Vega, E.A., Nicolaescu, D., Salehi, O., Stone, J., Yang, J., Rizack, T., Cook, N., Sorescu, G., Ward, P., Mehta, A., Caprario, L., Kozyreva, O., Conrad, C.

Get full text

Is squamous cell histology an adverse prognosticator for survival of malignancies of the upper urinary tract? by Rizack, T., Mega, A., Berz, D.

“…Abstract only 6617 Background: Carcinomas of the renal pelvis and ureter are rare diseases, accounting for only about 1% of all urogenital malignancies…”
Get full text

Is tumor board relevant? by Dizon, D. S., Gass, J., Legare, R. D., Sakr, B. J., Rizack, T.

“…Abstract only…”
Get full text

P3-06-01: Next Generation RNA Sequencing Reveals Changes in Gene Expression and Alternative Splicing upon Brief Exposure to Therapy in Early Breast Cancer by Varadan, V, Kamalakaran, S, Janevski, A, Banerjee, N, Lezon-Geyda, K, Bossuyt, V, Flowers, D, Sikov, W, Abu-Khalaf, M, Rizack, T, Dimitrova, N, Harris, LN

“…Abstract Background The use of next generation RNA sequencing (RNA-seq) allows for the characterization of the transcriptome at levels of detail unachievable…”
Get full text

P3-06-04: Sno/miRNA Expression Via Next Generation Sequencing: Variation in Patients before and after Treatment by Banerjee, N, Kamalakaran, S, Varadan, V, Janevski, A, Lezon-Geyda, K, Bossuyt, V, Flowers, D, Sikov, W, Abu-Khalaf, M, Rizack, T, Harris, L, Dimitrova, N

“…Abstract Background Aberrant expression of small RNA molecules has been shown in breast cancer. It is yet unclear if variation exists in small RNA molecule…”
Get full text

Evaluation of ER/PR and HER2 status by RNA sequencing in tissue core biopsies from preoperative clinical trial specimens by Kamalakaran, S., Lezon-Geyda, K., Varadan, V., Banerjee, N., Lannin, D. R., Rizack, T., Sikov, W. M., Abu-Khalaf, M. M., Janevski, A., Harris, L.

“…Abstract only 46 Background: Next-generation sequencing for measuring RNA (RNASeq) offer increased sensitivity, dynamic range and provide unbiased detection of…”
Get full text

Carboplatin (Cb), weekly nanoparticle, albumin-bound paclitaxel (wAb), and bevacizumab (Av) neoadjuvant chemotherapy (NAC) in HER2-negative breast cancer (BrCA): A BrUOG study by Sinclair, N., Abu-Khalaf, M. M., Sakr, B. J., Rizack, T., Lannin, D. R., Gass, J. S., Strenger, R., Bossuyt, V., Fenton, M. A., Harris, L., Sikov, W. M.

“…Abstract only…”
Get full text

Neoadjuvant therapy for stage II-III breast cancer with weekly nab-paclitaxel, every-three-week carboplatin, and targeted agents: Interim dose delivery and toxicity data by Rizack, T., Abu-Khalaf, M. M., Legare, R. D., Strenger, R., Fenton, M. A., Sakr, B. J., Kennedy, T. A., Harris, L., Sikov, W. M.

“…Abstract only…”
Get full text